Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to

advanced cancer
cancer
  • 226 views
  • 10 May, 2022
  • 4 locations
Featured trial
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to

carcinoma
urothelial carcinoma
ovarian cancer
metastatic cervical cancer
  • 380 views
  • 10 May, 2022
  • 4 locations
Featured trial
Tralokinumab monotherapy for moderate to severe atopic dermatitis

Clinical research study for the treatment of moderate to severe atopic dermatitis.

  • 1371 views
  • 07 Nov, 2020
  • 1 location
Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug (POLYbio)

The combination of methotrexate (MTX) with a biological disease-modifying antirheumatic drugs (bDMARD) is the next step in treatment with MTX monotherapy in rheumatoid arthritis (RA). Estimation of MTX and bDMARD impregnation could be performed with the erythrocyte MTX polyglutamate (MTX-PG) and bDMARD assays before to move to a second bDMARD. …

methotrexate
DMARD
remission
antirheumatics
  • 2 views
  • 21 Mar, 2022
  • 1 location
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (TILDVIT-1227)

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

hypopigmentation
  • 0 views
  • 28 Apr, 2022
  • 1 location
The Norwegian Antirheumatic Drug Register

NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the …

  • 10 views
  • 21 Jan, 2021
  • 7 locations